These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7594671)

  • 1. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease.
    Schoen RT; Meurice F; Brunet CM; Cretella S; Krause DS; Craft JE; Fikrig E
    J Infect Dis; 1995 Nov; 172(5):1324-9. PubMed ID: 7594671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
    Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
    Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine.
    Schoen RT; Deshefy-Longhi T; Van-Hoecke C; Buscarino C; Fikrig E
    Clin Ther; 2003 Jan; 25(1):210-24. PubMed ID: 12637121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine.
    Keller D; Koster FT; Marks DH; Hosbach P; Erdile LF; Mays JP
    JAMA; 1994 Jun; 271(22):1764-8. PubMed ID: 8196120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.
    Feder HM; Beran J; Van Hoecke C; Abraham B; De Clercq N; Buscarino C; Parenti DL
    J Pediatr; 1999 Nov; 135(5):575-9. PubMed ID: 10547245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.
    Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S
    Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
    Molloy PJ; Berardi VP; Persing DH; Sigal LH
    Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
    Wressnigg N; Barrett PN; Pöllabauer EM; O'Rourke M; Portsmouth D; Schwendinger MG; Crowe BA; Livey I; Dvorak T; Schmitt B; Zeitlinger M; Kollaritsch H; Esen M; Kremsner PG; Jelinek T; Aschoff R; Weisser R; Naudts IF; Aichinger G
    Clin Vaccine Immunol; 2014 Nov; 21(11):1490-9. PubMed ID: 25185574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.
    Sigal LH; Zahradnik JM; Lavin P; Patella SJ; Bryant G; Haselby R; Hilton E; Kunkel M; Adler-Klein D; Doherty T; Evans J; Molloy PJ; Seidner AL; Sabetta JR; Simon HJ; Klempner MS; Mays J; Marks D; Malawista SE
    N Engl J Med; 1998 Jul; 339(4):216-22. PubMed ID: 9673299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant vaccine for Lyme disease.
    Wallich R; Kramer MD; Simon MM
    Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
    Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
    N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults.
    Van Hoecke C; Comberbach M; De Grave D; Desmons P; Fu D; Hauser P; Lebacq E; Lobet Y; Voet P
    Vaccine; 1996 Dec; 14(17-18):1620-6. PubMed ID: 9032890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.
    Schoen RT; Sikand VK; Caldwell MC; Van Hoecke C; Gillet M; Buscarino C; Parenti DL
    Clin Ther; 2000 Mar; 22(3):315-25. PubMed ID: 10963286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Schlegl R; Lundberg U
    Vaccine; 2015 Nov; 33(44):5982-8. PubMed ID: 26277070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
    Zhao H; Bao FF; Liu A
    J Infect Dev Ctries; 2017 Jan; 11(1):1-9. PubMed ID: 28141584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Lyme disease after OspA vaccine.
    Schutzer SE; Luan J; Coyle PK
    N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653
    [No Abstract]   [Full Text] [Related]  

  • 19. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
    Beran J; De Clercq N; Dieussaert I; Van Hoecke C
    Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of OspA vaccination on Lyme disease serologic testing.
    Aguero-Rosenfeld ME; Roberge J; Carbonaro CA; Nowakowski J; Nadelman RB; Wormser GP
    J Clin Microbiol; 1999 Nov; 37(11):3718-21. PubMed ID: 10523583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.